CPI-17 Antibody (C-1): sc-365841

CPI-17 Antibody (C-1) is a mouse monoclonal IgG1 kappa light chain antibody that detects CPI-17 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-CPI-17 antibody (C-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CPI-17 plays a crucial role as a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphatase, which is essential for regulating smooth muscle contraction. CPI-17 is primarily located in smooth muscle tissues, where CPI-17 modulates myosin phosphatase activity, thereby influencing muscle contraction and relaxation. Phosphorylation of CPI-17 at Threonine 38, mediated by protein kinase C or Rho-kinase, significantly enhances inhibitory effect on myosin phosphatase, contributing to calcium sensitization during smooth muscle contraction. CPI-17 is also phosphorylated at Serine 12 and Threonine 38 by MYPT-associated kinase, M110 kinase, further underscoring CPI-17′s importance in smooth muscle physiology and potential implications in various cardiovascular and gastrointestinal disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CPI-17 Antibody (C-1) References:

1. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility.  |  Kitazawa, T., et al. 2000. J Biol Chem. 275: 9897-900. PMID: 10744661
2. Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase.  |  Koyama, M., et al. 2000. FEBS Lett. 475: 197-200. PMID: 10869555
3. Inhibition of myosin/moesin phosphatase by expression of the phosphoinhibitor protein CPI-17 alters microfilament organization and retards cell spreading.  |  Eto, M., et al. 2000. Cell Motil Cytoskeleton. 46: 222-34. PMID: 10913968
4. Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N.  |  Hamaguchi, T., et al. 2000. Biochem Biophys Res Commun. 274: 825-30. PMID: 10924361
5. Dual Ser and Thr phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by MYPT-associated kinase.  |  MacDonald, JA., et al. 2001. FEBS Lett. 493: 91-4. PMID: 11287002
6. Phosphorylation of CPI17 and myosin binding subunit of type 1 protein phosphatase by p21-activated kinase.  |  Takizawa, N., et al. 2002. Biochem Biophys Res Commun. 297: 773-8. PMID: 12359219
7. Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits.  |  Eto, M., et al. 2004. Proc Natl Acad Sci U S A. 101: 8888-93. PMID: 15184667
8. Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells.  |  Xie, Z., et al. 2006. Cardiovasc Res. 69: 491-501. PMID: 16336954
9. Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors.  |  Eto, M. 2009. J Biol Chem. 284: 35273-7. PMID: 19846560
10. High fat diet confers vascular hyper-contractility against angiotensin II through upregulation of MLCK and CPI-17.  |  Kim, JI. 2017. Korean J Physiol Pharmacol. 21: 99-106. PMID: 28066146
11. CPI-17-mediated contraction of vascular smooth muscle is essential for the development of hypertension in obese mice.  |  Sun, J., et al. 2019. J Genet Genomics. 46: 109-118. PMID: 30948334
12. Identification of trimeric myosin phosphatase (PP1M) as a target for a novel PKC-potentiated protein phosphatase-1 inhibitory protein (CPI17) in porcine aorta smooth muscle.  |  Senba, S., et al. 1999. J Biochem. 125: 354-62. PMID: 9990134

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CPI-17 Antibody (C-1) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CPI-17 Antibody (C-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CPI-17 Antibody (C-1) Specifications

Alternate Product Name: CPI-17

Product Clone Name: C-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CPI-17

Epitope Species: human

Product Reactivity/Detection: CPI-17

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CPI-17 Antibody (C-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin